ABCURO

Newton, Massachusetts, November 11, 2024- Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced that Alex Martin, Chief Executive Officer, will present at the following investor conferences. Stifel 2024 Healthcare Conference: Presentation on November 18, 2024, at 3:00 pm... Precision Targeting of Highly Cytotoxic T Cells in Autoimmune Disease.

Also known as: Abcuro, Inc.

Primary location: Newton United States